drugset
drugset / Trial / NCT03617510

A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China

NCT03617510 ↗

Phase 1 Completed 48 enrolled Shijiazhuang Yiling Pharmaceutical Co. Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

1. To evaluate the tolerances of healthy subjects treated with Felbinac Trometamol Injection on multiple dose and single dose 2. To evaluate the pharmacokinetic characteristics in healthy subjects treated with Felbinac Trometamol Injection on multiple dose and single dose 3. To provide the basis for the dose for the follow-up clinical study.

Timeline

Start
2018-07-10
Primary completion
2018-11-05
Completion
2019-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Felbinac Trometamol Unknown 47.13 mg Intravenous
Subject Felbinac Trometamol Unknown 94.25 mg Intravenous
Subject Felbinac Trometamol Unknown 188.5 mg Intravenous
Subject Felbinac Trometamol Unknown 259.16 mg Intravenous

Indications

No indication recorded.